Venture Corp.'s Lifestyle, Consumer, Life Sciences Segments Could Recover in 2027
Dow Jones
Sep 14
0443 GMT - Venture Corp.'s lifestyle and consumer products, as well as life sciences segments are likely to recover in 2027, supporting its earnings, says DBS Group Research's Lee Keng Ling in a note. The Singapore technology company is expected to launch a product in 4Q under its lifestyle and consumer products division, which should support the business's volume recovery and higher product value, the analyst says. Meanwhile, its life sciences segment is stabilizing from a recent downturn and should turn into a growth avenue around 2027, she says. DBS raises its 2026-2028 earnings estimates by 4%-5%. It raises its target price to 22.90 Singapore dollars from S$21.80 and maintains a buy rating. Shares rise 0.7% to S$16.78.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.